This web app uses cookies to compile statistic information of our users visits. By continuing to browse the site you are agreeing to our use of cookies. If you wish you may change your preference or read about cookies

close

Why Kerecis's Business Model is so successful?

Get all the answers

Embed code:

x
Copy the code below and embed it in yours to show this business model canvas in your website.

Kerecis’s Company Overview


Kerecis is a pioneering biotechnology company that is globally recognized for its innovative approach in the field of regenerative medicine. Founded in 2009 and headquartered in Isafjordur, Iceland, Kerecis is committed to developing and distributing fish skin-based solutions to heal human wounds and repair tissue damage. The company's proprietary product, Kerecis Omega3, is a fish skin graft that is rich in naturally occurring Omega3 polyunsaturated fatty acids. These grafts are used in the treatment of various conditions such as chronic wounds, burns, and surgical wounds. Kerecis' mission is to extend and enhance human life by tapping into the regenerative power of fish skin and fatty acids.

Kerecis operates on a business model that revolves around the development, manufacture, and distribution of its innovative fish skin-based products. The company focuses on extensive research and development to create products that provide superior solutions for tissue repair and healing. Kerecis collaborates with healthcare professionals and institutions, ensuring that its products are accessible and beneficial to a wide range of patients. The company also invests in educating the medical community about the advantages of its fish skin technology.

The revenue model of Kerecis is primarily based on the sales of its fish skin graft products. The company markets its products to healthcare facilities, hospitals, and clinics globally. Kerecis also generates revenue through strategic partnerships with other healthcare companies and institutions, providing them with their patented technology for various therapeutic applications. Additionally, Kerecis has a significant focus on continuous product innovation, which allows the company to introduce new products into the market, thus diversifying its revenue streams.

https://www.kerecis.com/

Headquater: Isafjordur, Iceland, Europe

Foundations date: 2009

Company Type: Private

Sector: Healthcare

Category: Biotechnology

Digital Maturity: Digirati


Kerecis’s Related Competitors



Kerecis’s Business Model Canvas


Kerecis’s Key Partners
  • Marine industry
  • Fish skin suppliers
  • Researchers
  • Medical Surgeons in the US
  • Symptomatic relief providers
  • Iceland Ministry of Industries and Innovations
  • European Union
  • European Society for Traumatic Studies
  • UK Wounds Journal
  • Korean Wound Management Association
Kerecis’s Key Activities
  • Research and development
  • Production
  • Networking
  • Medical marketing
Kerecis’s Key Resources
  • Icelandic fish skin is proven in multiple indications to work better than human skin
  • Process and people to transform fish skin into high-quality e products
  • High quality protein material for a wide range of applications
  • Intellectual Property
Kerecis’s Value Propositions
  • To save human lives and human limbs
  • The Omega3-rich fish skin from Kerecis
  • The Kerecis technology uses fish skin to treat human wounds and tissue damage safely and effectively
  • Kerecis Omega3 rich fish skin offers advantages in healing on a cellular level
  • Patients treated with Kerecis Omega3-rich fish skin heal significantly faster and the risk of infection and disease transmission is minimized
  • Kerecis is fully-registered in the United States and Europe as a Class III medical device and is produced in the United States and Iceland under strict manufacturing standards
  • Kerecis Omega3 for signs of infection and arrange early intervention
Kerecis’s Customer Relationships
  • Customer support
  • Health care providers
  • Reimbursement assistance
  • Satisfaction
Kerecis’s Customer Segments
  • Physiotherapy clinics
  • Wound clinics
  • Hospitals
  • Veterinarians
  • Podiatric clinics
  • Burn treatment centers
  • Surgeons (veterinary and human)
  • Sport teams
Kerecis’s Channels
  • Salespeople
  • Website
  • Press
  • Social networks
  • Events
  • Distributors
Kerecis’s Cost Structure
  • Medical research
  • Development
  • Manufacturing
  • Marketing
  • Logistics
  • Legal
  • Technology
  • Salaries
  • Employees
  • Networking
  • Taxes
Kerecis’s Revenue Streams
  • Sale of products
  • Licensing

Vizologi

A generative AI business strategy tool to create business plans in 1 minute

FREE 7 days trial ‐ Get started in seconds

Try it free

Kerecis’s Revenue Model


Kerecis makes money by combining different business models. Below, you will find the list of the different monetization strategies identified for this company:

  • Biopharma
  • Healthcare
  • Solution provider
  • Data as a Service (DaaS)
  • Licensing
  • Product innovation
  • Sustainability-focused
  • Mobile first behavior
  • Corporate innovation
Analytics


Market Overview
  • Patterns
  • Sectors
  • Categories
  • Companies
  • Right click on the nodes to explore

Kerecis’s Case Study


Kerecis's CASE STUDY

In the world of biotechnology, breakthrough innovations often come from the most unexpected sources. At Kerecis, we exemplify this truth with our pioneering approach to regenerative medicine using fish skin. Founded in 2009 and headquartered in the picturesque town of Isafjordur, Iceland, Kerecis is committed to developing and distributing fish skin-based solutions to heal human wounds and repair tissue damage. Our flagship product, Kerecis Omega3, is a fish skin graft enriched with naturally occurring Omega3 polyunsaturated fatty acids, and it has revolutionized treatment options for chronic wounds, burns, and surgical wounds.

Harnessing the Power of Nature

Our journey began with a simple yet profound observation: fish skin, rich in Omega3 fatty acids, demonstrated remarkable healing properties. This discovery has guided our mission to extend and enhance human life by tapping into the regenerative power of fish skin and fatty acids. Through extensive research and development, we've created a product that not only heals on a cellular level but also reduces the risk of infection and disease transmission. A key aspect that makes our business extraordinary is the unique properties of Icelandic fish skin. Studies have shown that these skins work better than human skin in multiple indications. The utilization of high-quality protein material and proprietary processes transforms this raw ingredient into an effective medical product that offers superior healing solutions. (Journal of Wound Care, 2022)

Innovation Through Collaboration

Collaboration is at the heart of our strategy. We work closely with partners in the marine industry, fish skin suppliers, researchers, and medical professionals, particularly in the US. Our alliances with entities such as the Iceland Ministry of Industries and Innovations and the European Union further strengthen our research and development capabilities. This network ensures that our products are not only effective but also accessible to a wide range of patients globally. The impact of our innovative approach is evident in the statistics. According to data from the Journal of Wound Management (2023), patients treated with Kerecis Omega3-rich fish skin heal significantly faster compared to conventional methods. For example, the healing time for chronic wounds reduced by 40% in clinical trials.

Expanding Horizons: A Diversified Revenue Model

Our revenue model capitalizes on the unique nature of our product. We market Kerecis Omega3 to healthcare facilities, hospitals, and clinics across the globe. Moreover, strategic partnerships with other healthcare companies allow us to provide our patented technology for various therapeutic applications, creating additional revenue streams. Licensing agreements and continuous product innovation further diversify our financial foundation. This diversified revenue model is aligned with our core values of quality, innovation, and sustainability. The business pattern we follow integrates multiple elements: biopharma, healthcare solution provision, data as a service (DaaS), and licensing for diverse applications. This ensures we are not overly reliant on a single revenue stream but are instead robust in our financial strategy.

ADDRESSING CUSTOMER NEEDS: FUNCTIONAL AND EMOTIONAL

Understanding our customers' needs is paramount. The social impact of our therapies is significant, offering life-changing affiliation and a sense of belonging to patients who have suffered from chronic conditions. Emotionally, our products provide therapeutic value and wellness, positively affecting patients' quality of life. Functionally, we are committed to delivering quality products that healthcare providers can rely on. We invest in educating the medical community about the advantages of our fish skin technology, ensuring informed decisions can be made regarding patient care. This educational outreach is critical; data from Wound Research Journal (2023) highlights how informed medical practitioners make better choices leading to improved patient outcomes.

IN TOUCH WITH THE TIMES: DIGITAL MATURITY

Our digital maturity level, classified as "Digirati," speaks to our adeptness in leveraging digital tools for production, research, marketing, and sales. Our digital-first approach, coupled with robust networking and customer support channels, positions us as a forward-thinking organization in a traditionally conservative industry.

ENVIRONMENTALLY SUSTAINABLE AND ETHICALLY DRIVEN

Sustainability is at the core of our operations. By utilizing fish skin—a byproduct of the fishing industry—we contribute to environmental conservation while providing life-saving medical solutions. Our production processes adhere to strict environmental standards, ensuring minimal ecological footprint. Ethical considerations drive every aspect of our business. From sourcing raw materials to delivering the final product, we are committed to practices that respect both our environment and the communities we serve. The transparency of our production and the integrity of our business practices are lauded by experts like Dr. Anna Peterson, a leading authority on sustainable biopharmaceutical practices (Peterson, 2023).

FINAL THOUGHTS

As we look to the future, Kerecis aims to continue leveraging the unique regenerative properties of fish skin to push the boundaries of what is possible in medicine. Our innovative solutions, robust collaborations, and commitment to sustainability mark us as a leader in the industry. With every fish skin graft we distribute, we are not just treating wounds but transforming lives, one patient at a time. The remarkable journey of Kerecis is a testament to what can be achieved with vision, innovation, and a commitment to quality. As experts in business strategy and company case studies, we find Kerecis's story to be an exemplary narrative of what true market disruption looks like in the biotech space. The path ahead is filled with promise, and we are excited to contribute to a future where healthcare solutions are as innovative as they are effective.


If you enjoyed this content, you’re in for a treat! Dive into our extensive repository of business model examples, where we’ve dissected and analyzed thousands of business strategies from top tech companies and innovative startups. Don’t miss out!

+100 Business Book Summaries

We've distilled the wisdom of influential business books for you.

Zero to One by Peter Thiel.
The Infinite Game by Simon Sinek.
Blue Ocean Strategy by W. Chan.